化合物Ilorasertib TQ0059

Product Introduction
Bioactivity


英文名: Ilorasertib

描述: Ilorasertib (ABT-348) 是一种 ATP 竞争性多靶点激酶抑制剂，可抑制 Aurora A、Aurora B 和Aurora C，IC50值为120 nM、7 nM 和1 nM。它还抑制 RET 酪氨酸激酶、PDGFRβ 和 Flt1，IC50为7 nM、3 nM 和 32 nM。

细胞实验: Noncycling primary HUVEC are used to assess the effect of Ilorasertib on nonproliferating cells. Cells (35,000/well) are seeded in growth medium in a 96-well tissue culture plate, and after 2 days, the medium is changed and the cells are treated with Ilorasertib. After an additional 3 days, cell viability is measured with Cell TiterGlo reagent [2].

动物实验: For flank xenograft models, cells are suspended in PBS, mixed with Matrigel (phenol red-free) in a ratio of 1:4 (v/v), and inoculated into the flank of female SCID/beige mice (5 million cells per site). Inoculated mice are randomized into groups of 10, and treatment is initiated when mean tumor volume is approximately 0.4 cm^3 or 0.5 cm^3. Tumor growth in the flank is assessed by measuring tumor size with calipers and calculating volume using the formula (L × W2/2). Study groups are terminated before tumor volume reaches 3 cm^3. Inhibition of tumor growth is assessed at the time the vehicle-treated group is terminated by calculating the ratio of the mean volume of the test drug group to the mean volume of the untreated (control) group (T/C) and calculating the percentage of inhibition of control [(1 ? T/C) × 100]. The dosing formulation of test agents is prepared by stepwise addition, with mixing, of the following reagents: EtOH, Tween 80, polyethylene glycol 400, and 2% hydroxypropyl methylcellulose (2:5:20:73, v/v). The dosing volume is 10 mL/kg [2].

体外活性: 除了针对Aurora激酶外，Ilorasertib还是VEGFR和PDGFR激酶家族的强效抑制剂，并在较小程度上抑制Src家族的胞质酪氨酸激酶。Ilorasertib能够依赖浓度地增加两种NSCLC细胞系展现多倍体的程度和数量（EC50: 5, 10 nM）。Ilorasertib对表达BCR-ABL的CML细胞以及表达Gleevec抗性BCR-ABL T315I突变的细胞显示出抗增殖活性（IC50: 47, 260 nM）[2]。

体内活性: Ilorasertib 在子宫水肿模型中有效抑制 VEGF 反应（ED50：0.2 mg/kg，静脉注射）。 Ilorasertib (25 mg/kg, s.c.) 可抑制从移植白血病模型获得的循环肿瘤细胞中的组蛋白 H3 磷酸化。 Ilorasertib（20 mg/kg，口服）可抑制人类异种移植模型中已形成肿瘤的生长并导致晚期肿瘤消退[2]。 Ilorasertib 在实体和血液异种移植模型中每周一次静脉、微型泵或肠胃外给药后显示出显着的抗肿瘤功效[3]。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 40 mg/mL (81.87 mM)


关键字: anti-tumor | H1299 | ABT348 | Platelet-derived growth factor receptor | Inhibitor | antiproliferative activity | AML | VEGFR | histone H3 phosphorylation | Vascular endothelial growth factor receptor | PDGFR | Aurora Kinase | inhibit | Ilorasertib | H460 cells | MDS | ABT 348

相关产品: SU5204 | Vorolanib | PP121 | AG-13958 | Vatalanib free base | KI8751 | Ribociclib | Motesanib Diphosphate | LY2874455 | ODM-203

相关库: Drug Repurposing Compound Library | Anti-Breast Cancer Compound Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Cancer Clinical Compound Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Active Compound Library | Bioactive Compound Library

化合物Ilorasertib TQ0059信息由TargetMol中国为您提供，如您想了解更多关于化合物Ilorasertib TQ0059报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途